RevMed’s pancreatic cancer drug breezes through with swift approval
Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule.
Therapy Area
Johnson & Johnson’s multiple myeloma treatment secures EC approval
Intismeran autogene a turning point for cancer vaccines
Updated UK guidance for finerenone introduces new treatment for HF patients
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
Evotec and Odyssey collaborate on AI-enabled R&D
Pfizer seeks label expansion for Litfulo after double Phase III NSV win
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
